Furosemide as a factor to deteriorate therapeutic efficacy of rifaximin in patients with decompensated cirrhosis.
Yoshihito UchidaShohei TsujiHayato UemuraJun-Ichi KouyamaKayoko NaikiKayoko SugawaraMasamitsu NakaoMie InaoNobuaki NakayamaYukinori ImaiTomoaki TomiyaSatoshi MochidaPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2020)
Furosemide contributed to the deteriorated outcome of patients receiving rifaximin. Consequently, rifaximin should be given before increasing the furosemide dose, and the furosemide dose should not be increased during rifaximin treatment.